Albireo Spotlights Global Patient Communities on Rare Disease Day
February 26, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Calls to unite global communities affected by rare diseases – – Albireo supports increasing education and advances in research for rare cholestatic liver diseases – BOSTON, Feb. 26, 2021 (GLOBE...
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
February 25, 2021 08:00 ET
|
Albireo Pharma, Inc.
– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch – – Announces odevixibat co-promotion agreement with Travere, a leading rare disease company – – ASSERT global pivotal...
Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
February 23, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced...
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
February 18, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 17, 2021 16:30 ET
|
Albireo Pharma, Inc.
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
Albireo Presents Odevixibat Commercialization Road to $1 Billion
February 11, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Company outlining large global rare cholestatic liver disease opportunity – – Advancing plans for anticipated odevixibat U.S. and EU launch, with focus on market access – – Expansion opportunity...
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
January 25, 2021 08:00 ET
|
Albireo Pharma, Inc.
- Company receives FDA Priority Review with PDUFA date set for July 20, 2021 - - Submission data for PFIC types 1, 2, 3, supporting once-daily use across a wide range of patients - - FDA has granted...
Albireo Recognizes International Alagille Syndrome Awareness Day 2021
January 22, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today joins the Alagille community...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 14, 2021 16:30 ET
|
Albireo Pharma, Inc.
BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
Albireo to Host Virtual Investor Commercial Day 2021
January 07, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a...